Tumors  ||| S:0 E:7 ||| NNS
of  ||| S:7 E:10 ||| IN
the  ||| S:10 E:14 ||| DT
urinary  ||| S:14 E:22 ||| JJ
system ||| S:22 E:28 ||| NN
.  ||| S:28 E:30 ||| .
Current  ||| S:30 E:38 ||| JJ
and  ||| S:38 E:42 ||| CC
old  ||| S:42 E:46 ||| JJ
problems  ||| S:46 E:55 ||| NNS
Principally  ||| S:55 E:67 ||| RB
there  ||| S:67 E:73 ||| EX
are  ||| S:73 E:77 ||| VBP
two  ||| S:77 E:81 ||| CD
different  ||| S:81 E:91 ||| JJ
types  ||| S:91 E:97 ||| NNS
of  ||| S:97 E:100 ||| IN
bladder  ||| S:100 E:108 ||| JJ
cancer ||| S:108 E:114 ||| NN
.  ||| S:114 E:116 ||| .
Non-invasive  ||| S:116 E:129 ||| JJ
papillary  ||| S:129 E:139 ||| JJ
low  ||| S:139 E:143 ||| JJ
grade  ||| S:143 E:149 ||| NN
tumors  ||| S:149 E:156 ||| NNS
( ||| S:156 E:157 ||| -LRB-
pTa  ||| S:157 E:161 ||| NNP
G1-G2 ||| S:161 E:166 ||| NNP
)  ||| S:166 E:168 ||| -RRB-
are  ||| S:168 E:172 ||| VBP
genetically  ||| S:172 E:184 ||| RB
stable ||| S:184 E:190 ||| JJ
,  ||| S:190 E:192 ||| ,
recur  ||| S:192 E:198 ||| VBD
frequently  ||| S:198 E:209 ||| RB
but  ||| S:209 E:213 ||| CC
show  ||| S:213 E:218 ||| VB
a  ||| S:218 E:220 ||| DT
low  ||| S:220 E:224 ||| JJ
risk  ||| S:224 E:229 ||| NN
of  ||| S:229 E:232 ||| IN
progression ||| S:232 E:243 ||| NN
.  ||| S:243 E:245 ||| .
On  ||| S:245 E:248 ||| IN
the  ||| S:248 E:252 ||| DT
other  ||| S:252 E:258 ||| JJ
hand  ||| S:258 E:263 ||| NN
there  ||| S:263 E:269 ||| EX
are  ||| S:269 E:273 ||| VBP
high  ||| S:273 E:278 ||| JJ
grade  ||| S:278 E:284 ||| NN
tumors  ||| S:284 E:291 ||| NNS
( ||| S:291 E:292 ||| -LRB-
pT1-4 ||| S:292 E:297 ||| NNP
,  ||| S:297 E:299 ||| ,
carcinoma  ||| S:299 E:309 ||| VBG
in  ||| S:309 E:312 ||| IN
situ ||| S:312 E:316 ||| CD
) ||| S:316 E:317 ||| -RRB-
,  ||| S:317 E:319 ||| ,
which  ||| S:319 E:325 ||| WDT
are  ||| S:325 E:329 ||| VBP
genetically  ||| S:329 E:341 ||| RB
unstable ||| S:341 E:349 ||| JJ
,  ||| S:349 E:351 ||| ,
show  ||| S:351 E:356 ||| VBP
biologically  ||| S:356 E:369 ||| JJ
aggressive  ||| S:369 E:380 ||| JJ
behaviour  ||| S:380 E:390 ||| NN
and  ||| S:390 E:394 ||| CC
progress ||| S:394 E:402 ||| NN
.  ||| S:402 E:404 ||| .
The  ||| S:404 E:408 ||| DT
distinction  ||| S:408 E:420 ||| NN
between  ||| S:420 E:428 ||| IN
non-invasive  ||| S:428 E:441 ||| JJ
( ||| S:441 E:442 ||| -LRB-
pTa ||| S:442 E:445 ||| NNP
)  ||| S:445 E:447 ||| -RRB-
and  ||| S:447 E:451 ||| CC
minimal-invasive  ||| S:451 E:468 ||| NNP
( ||| S:468 E:469 ||| -LRB-
pT1 ||| S:469 E:472 ||| NNP
)  ||| S:472 E:474 ||| -RRB-
is  ||| S:474 E:477 ||| VBZ
one  ||| S:477 E:481 ||| CD
of  ||| S:481 E:484 ||| IN
the  ||| S:484 E:488 ||| DT
most  ||| S:488 E:493 ||| RBS
challenging  ||| S:493 E:505 ||| JJ
areas  ||| S:505 E:511 ||| NNS
in  ||| S:511 E:514 ||| IN
bladder  ||| S:514 E:522 ||| JJ
pathology ||| S:522 E:531 ||| NN
.  ||| S:531 E:533 ||| .
Due  ||| S:533 E:537 ||| JJ
to  ||| S:537 E:540 ||| TO
the  ||| S:540 E:544 ||| DT
lack  ||| S:544 E:549 ||| NN
of  ||| S:549 E:552 ||| IN
appropriate  ||| S:552 E:564 ||| JJ
auxiliary  ||| S:564 E:574 ||| JJ
analysis  ||| S:574 E:583 ||| NN
the  ||| S:583 E:587 ||| DT
diagnosis  ||| S:587 E:597 ||| NN
is  ||| S:597 E:600 ||| VBZ
based  ||| S:600 E:606 ||| VBN
entirely  ||| S:606 E:615 ||| RB
on  ||| S:615 E:618 ||| IN
histopathology ||| S:618 E:632 ||| NN
.  ||| S:632 E:634 ||| .
P53  ||| S:634 E:638 ||| NN
immunohistochemistry  ||| S:638 E:659 ||| NNS
can  ||| S:659 E:663 ||| MD
be  ||| S:663 E:666 ||| VB
helpful  ||| S:666 E:674 ||| JJ
in  ||| S:674 E:677 ||| IN
the  ||| S:677 E:681 ||| DT
assessment  ||| S:681 E:692 ||| NN
of  ||| S:692 E:695 ||| IN
recurring  ||| S:695 E:705 ||| VBG
high  ||| S:705 E:710 ||| JJ
grade  ||| S:710 E:716 ||| NN
neoplasia ||| S:716 E:725 ||| NN
.  ||| S:725 E:727 ||| .
Targeted  ||| S:727 E:736 ||| JJ
therapy  ||| S:736 E:744 ||| NN
in  ||| S:744 E:747 ||| IN
bladder  ||| S:747 E:755 ||| JJ
cancer  ||| S:755 E:762 ||| NN
is  ||| S:762 E:765 ||| VBZ
particularly  ||| S:765 E:778 ||| RB
interesting ||| S:778 E:789 ||| JJ
,  ||| S:789 E:791 ||| ,
since  ||| S:791 E:797 ||| IN
a  ||| S:797 E:799 ||| DT
high  ||| S:799 E:804 ||| JJ
number  ||| S:804 E:811 ||| NN
of  ||| S:811 E:814 ||| IN
oncogenes  ||| S:814 E:824 ||| NNS
are  ||| S:824 E:828 ||| VBP
activated  ||| S:828 E:838 ||| VBN
and  ||| S:838 E:842 ||| CC
overexpressed  ||| S:842 E:856 ||| NNS
( ||| S:856 E:857 ||| -LRB-
e.g.  ||| S:857 E:862 ||| NNP
HER2  ||| S:862 E:867 ||| NNP
and  ||| S:867 E:871 ||| CC
EGFR ||| S:871 E:875 ||| NNP
) ||| S:875 E:876 ||| -RRB-
.  ||| S:876 E:878 ||| .
